RVTY

Business Profile & Competitive Position

Revvity, Inc. is a Healthcare company in the Medical - Diagnostics & Research industry. It describes itself as a health science solutions company, providing technologies, expertise and services that span complete workflows from discovery through development and from diagnosis to cure. Its operations are split into two segments. Life Sciences supplies reagents, instruments, software and services that accelerate drug discovery and development. Diagnostics provides instruments, reagents, assay platforms and software focused on reproductive health, immunodiagnostics and emerging-market diagnostics. The company is headquartered in Waltham, Massachusetts, and markets its products and services in more than 160 countries.

The margin and return figures ground the competitive story in numbers. Revvity’s net margin is 8.2% and its return on equity is 3.3%. That means the company retains roughly $0.082 of every revenue dollar as net income, and it generates modest accounting returns on its equity base. Those numbers do not point to a wide, pricing-power-driven moat. Instead, they suggest the competitive position rests on scale, workflow breadth, geographic reach and specialized customer relationships. Strength in diagnostics and research tools often shows up as higher returns on capital; Revvity’s current profile is more consistent with a solid, integrated player than with a dominant franchise.

Scale is real, even if returns are muted. As of December 28, 2025, Revvity employed approximately 11,000 people, including roughly 2,000 sales and service representatives in about 40 countries. The company sells primarily through specialized sales forces and uses distributors where it lacks direct coverage, a model that can extend reach without fully building out local infrastructure.

Financial Posture

Revvity’s market capitalization is $16.0 billion, and the stock was recently quoted at $143.77. The price-to-earnings ratio is 68.5, a steep multiple given the current profitability profile. Net margin is 8.2% and ROE is 3.3%, so the market is paying a large premium relative to the company’s current per-dollar earnings and equity returns. The beta is 1.09, indicating the stock has moved slightly more than the broad market on average.

The technical snapshot adds context. The 50-day exponential moving average is $123.00, which means price is trading roughly $20.77 above that short-term trend. The RSI is 69.5, just under the commonly watched 70 overbought threshold. The central financial tension is the gap between a valuation multiple of 68.5x earnings and an ROE of only 3.3%. Traders looking at the stock must decide whether the strategic pipeline can eventually justify that valuation, because today’s reported profitability and returns do not.

Strategic Priorities & Outlook

Revvity’s most recent SEC 10-K filing lays out four near-term priorities:

• Strengthen key markets by expanding global product and service offerings, maintaining superior product quality and enhancing the customer experience.
• Accelerate transformational innovation through internal R&D, third-party collaborations and strategic acquisitions or licensing.
• Advance the use of Artificial Intelligence to strengthen differentiated offerings and drive internal operating efficiencies.
• Maintain disciplined capital allocation to support organic investment, mergers and acquisitions and opportunistic share repurchase programs.

The filing also notes that, as of December 28, 2025, Revvity employed approximately 11,000 people, with about 2,000 sales and service representatives operating in roughly 40 countries. Distribution is mostly through specialized sales forces, supplemented by distributors in regions without direct sales or service coverage.

One operational risk stands out. The company states that certain principal products rely on a limited or single qualified source for critical raw materials and components, and that it periodically purchases quantities ahead of manufacturing needs. For a diagnostics company, reagent continuity and supply predictability matter, so that single-source exposure is a concrete factor in the operational outlook. The strategic focus on M&A and AI also implies the growth path depends partly on successfully integrating acquired assets and translating AI investments into measurable efficiency or differentiation.

Macro & Geopolitical Exposure

RVTY’s classification in Medical - Diagnostics & Research places it at the intersection of healthcare regulation, reimbursed clinical testing and life-sciences capital equipment. At a sector level, the business is exposed to several macro themes:

• Regulatory risk: diagnostic assays, instruments and software face FDA and international regulatory pathways, including clearances, approvals and post-market surveillance.
• Reimbursement policy: clinical diagnostic utilization depends on Medicare, Medicaid and private-payer coverage decisions, which can shift volume and pricing.
• Customer capital budgets: hospitals, reference labs and academic institutions set capital spending cycles for instruments, introducing demand volatility.
• Trade policy and tariffs: instruments and specialty reagents cross borders; tariff changes can affect product costs and installed-base economics.
• Currency exposure: with products marketed in more than 160 countries, foreign-exchange translation can affect reported revenue and expenses.
• Supply-chain concentration: the industry relies on highly specific antibodies, chemicals, chips and optical components, where qualifying alternative suppliers can take time.
• R&D spending by pharma and biotech: Life Sciences revenue is partly tied to drug-discovery budgets, which can contract when funding tightens.

These are industry-level exposures grounded in the diagnostics and research-tools sector, not firm-specific risks invented for Revvity alone.

Recent Developments

Recent news flow has centered on investor conferences, relative valuation comparisons and a sharp price move. On September 14, 2026, Seeking Alpha published the transcript of Revvity’s presentation at the Morgan Stanley 24th Annual Global Healthcare Conference. The following day, September 15, 2026, Seeking Alpha also published the transcript of Revvity’s appearance at the 2026 Global Healthcare Conference.

On September 16, 2026, Zacks ran the headline “Strength Seen in Revvity (RVTY): Can Its 9.1% Jump Turn into More Strength?”—a reference to a strong recent price move. On September 18, 2026, defenseworld.net published “Critical Survey: Revvity (NYSE:RVTY) vs. Cytek Biosciences (NASDAQ:CTKB).”

This sequence shows that sentiment was already active ahead of the next earnings report, scheduled for October 26, 2026 before the market open. The conference transcripts suggest management’s messaging was a near-term catalyst, while the 9.1% jump and the current RSI of 69.5 show the stock had stretched above its $123.00 50-day EMA by late September.

Earnings Behavior & Post-Earnings Drift

Revvity’s earnings track record has been strong on the headline numbers. Over the last eight reported quarters, the company has beaten consensus estimates every time, for a beat rate of 8 out of 8, or 100%. The average earnings surprise across those quarters is 7.2%. The average five-trading-day price move after earnings is 0.8% to the upside, classified as an “up” drift.

Those averages hide meaningful quarter-to-quarter variation. In the four most recent reports, EPS exceeded estimates in each case, but price reactions were not uniformly positive:

• On August 4, 2026, Revvity reported $1.41 versus a $1.21 estimate, a 16.5% surprise. The stock rose 3.26% the next day and 3.9% over the following five sessions.
• On May 5, 2026, EPS came in at $1.06 versus a $1.02 estimate, a 3.9% surprise. The stock jumped 7.36% the next day and 7.58% over the next five sessions.
• On February 2, 2026, EPS was $1.70 versus a $1.57 estimate, an 8.3% surprise. The stock fell 5.57% the next day and 3.99% over the next five sessions.
• On October 27, 2025, EPS was $1.18 versus a $1.14 estimate, a 3.5% surprise. The stock declined 0.73% the next day and 4.31% over the next five sessions.

That pattern matters for interpreting the next report. Beats alone have not guaranteed post-earnings strength. The size of the beat, the tone of guidance, sector rotation and broader market conditions all appear to influence direction. On October 26, 2026, before the market open, Revvity is scheduled to report again, with a consensus EPS estimate of $1.28. The unofficial consensus—the market's real expectation—likely includes assumptions about beat magnitude and any forward commentary, so a published estimate of $1.28 may understate the hurdle the company needs to clear.

For a more comprehensive view of how institutions are weighing Revvity’s valuation, earnings setup and sector outlook heading into the October 26, 2026 report, explore the full institutional verdict and consensus breakdown in the platform’s deeper research tools.